Neonates with congenital gastrointestinal surgical conditions (CGISCs) are at risk of gut dysbiosis, infections and suboptimal neurodevelopment. There is biological plausibility that attenuating dysbiosis may improve their outcomes. Our prospective study (n=73) found that compared to healthy infants, neonates with CGISCs had lower levels of stool bifidobacteria and biologically important short-chain fatty acids (SCFA). Hence, we conducted a pilot RCT (n=61), which found that bifidobacteria (probiotic) supplementation attenuated dysbiosis, and improved stool SCFA levels and head growth. We then provided guidelines for conducting large RCTs to evaluate the role of probiotics in improving their clinical and neurodevelopmental outcomes.
|Qualification||Doctor of Philosophy|
|Award date||25 May 2022|
|Publication status||Unpublished - 2022|